KFDA approves zoledronic acid

Published: 2002-12-16 06:58:00

Updated: 2002-12-16 06:58:00

Novartis Korea announced that it has recently received marketing authorization from the Korea Food and Drug Administration for Zometa (zoledronic acid), a highly potent intravenous bisphosphonate, for the treatment of musculoskeletal disorders or bone complications associated with bone metastatis...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK